Rama Shankar Singh*

Research and Development, GEN-MED R&D, LLC, Orlando, FL 32817, USA

*Corresponding Author: Rama Shankar Singh, Research and Development, GEN-MED R&D, LLC, Orlando, FL 32817, USA. Email: gen-med@comcast.net

Received: July 15, 2025; Published: August 06, 2025

Abstract

After a decade of pioneering research, I have successfully developed the first Quadruplet Expanded DNA (QED) code for eukaryotic cells. This groundbreaking genetic system builds on the natural DNA bases (T, C, A, and G) to establish twenty independent, non-degenerate protein-coding and thirty-five distinct regulatory codons. These regulatory elements enable precise control of gene transcription, post transaction RNA splicing, and translating mRNA for protein synthesis across eukaryotes, viruses, and prokaryotes.

QED overcomes the limitations of the long-standing prokaryotic triplet genetic code and the orthogonal expanded quadruplet genetic code designed for unnatural amino acids. By facilitating the creation of functional proteins that maintain cellular homeostasis—and correcting dysfunctional proteins that cause disease—QED opens new frontiers in gene therapy.

This transformative technology holds the potential to revolutionize therapeutic strategies by enabling the repair of defective proteins and their underlying genetic sequences at both the DNA and protein levels, marking a paradigm shift in the treatment of genetic disorders and ushering in a new era of molecular medicine.

 Keywords: QED (Quadruplet Expanded DNA); Human Diseases

References

1. Rama Shankar Singh. “Quadruplet Expanded DNA (QED) Genetic Code for Eukaryotic Cells". Acta Scientific Medical Sciences12 (2023): 70-82.
2. Rama Shankar Singh. “Correlation between Eukaryotic Noncoding QED Genetic Codes and Cis-Regulatory Elements". Acta Scientific Medical Sciences10 (2024): 89-96.
3. Rama Shankar Singh. “QED Eukaryote Genetic Code and Principle of Information Flow and Biological Protein Synthesis”. Acta Scientific Medical Sciences6 (2025): 100-114.
4. Crick FH. “On the genetic code”. Science 139 (1963): 461-464.
5. Liu CC and Schultz PG. “Adding new chemistries to the genetic code”. Annual Review of Biochemistry 79 (2010): 413-444.
6. Malyshev DA., et al. “Efficient and sequence-independent replication of DNA containing a third base pair establishes a functional six-letter genetic alphabet”. Proceedings of the National Academy of Sciences of the United States of America. (2012): 12005-12010.
7. Hoshika S., et al. “Hachimoji DNA and RNA: a genetic system with eight building blocks”. Science 363 (2019): 884-887.
8. Kenneth S Kosik. “A Biologist talks to a Physicist”. Nature 557 (2020): 281.
9. Sarah Bohndiek. “A Physicist talks to a Biologist”. Nature 557 (2020): 283.
10. Claude E Shannon. “A Mathematical Theory of Communication”. The System Technical Journal 27 (1948): 379-423, 623-656.
11. 1968 The Nobel Prize in Physiology or Medicine was awarded jointly to Robert W. Holley, Har Gobind Khorana and Marshall W. Nirenberg "for their interpretation of the genetic code and its function in protein synthesis".
12. AR Morgan., et al. “Studies on polynucleotides, LIX. Further codon assignments from amino Acid incorporations directed by ribopolynucleotides containing repeating trinucleotide sequences”. Proceedings of the National Academy of Sciences of the United States of America 56 (1966): 1899-1906.
13. Nirenberg M and Leder P. “RNA codewords and protein synthesis. The effect of trinucleotides upon the binding of sRNA to ribosomes”. Science 145 (1964): 1399-1407.
14. Jones O W and Nirenberg M W. “Qualitative survey of RNA codewords”. Proceedings of the National Academy of Sciences of the United States of America 48 (1962): 2115-2123.
15. FIRST - Foundation for Ichthyosis & Related Skin Types, Inc.
16. Joosten MDW., et al. “New development in the molecular treatment of Ichthyosis_ Reve. of literature”. Orphanet Journal of Rare Diseases (2022)17-269
17. Kelsell David P., et al. “Mutations in ABCA12 Underlie the Severe Congenital Skin Disease HI”. American Journal of Human Genetics 76 (2005): 794-803.
18. Anna C Thomas., et al. “ABCA12 Is the Major Harlequin Ichthyosis Gene”. Journal of Investigative Dermatology 126 (2006): 2408-2413.
19. Akiyama Masashi., et al. “Mutations in lipid transporter ABCA12 in harlequin ichthyosis and functional recovery by corrective gene transfer”. Journal of Clinical Investigation 15 (2005): 1777-1784.
20. Hunt John F., et al. “Cystic Fibrosis Transmembrane Conductance Regulator (ABCC7) Structure”. Cold Spring Harbor Perspectives in Medicine 3 (2013): a009514.
21. Ratjen Felix., et al. “Cystic fibrosis”. Nature Reviews Disease Primers 1 (2015): 15010.
22. Hartmut Grasemann and Felix Ratjen. “Cystic Fibrosis”. NEJM 389 (2023): 1693 .
23. Inusa Baba PD., et al. “Sickle Cell Disease—Genetics, Pathophysiology, Clinical Presentation and Treatment”. International Journal of Neonatal Screening 5 (2019): 20.
24. George Q Daley. “Welcoming the Era of Gene Editing in Medicine”. The New England Journal of Medicine (2024).
25. Frangoul H., et al. “CRISPR-Cas9 Gene Editing for Sickle Cell disease and beta-Thalassemia”. The New England Journal of Medicine 384 (2021): 252-260.
26. Doerfle Phillip A., et al. “Genetic therapies for the first molecular disease”. Journal of Clinical Investigation8 (2021): e146394.
27. Sharma A., et al. “CRISPR-Cas9 Editing of the HBG1 and HBG2 Promoters to Treat Sickle Cell Disease”. NEJM 389 (2019): 820-832.
28. John Hardy and Dennis J Selkoe. “The Amyloid Hypothesis of Alzheimer’s Disease_ progress and problems on the road to therapeutics”. Science 297 (2021): 353-356.
29. Arnsten Amy FT., et al. “Hypothesis: Tau pathology is an initiating factor in sporadic Alzheimer’s disease”. Alzheimer 's Dementia 17 (2021): 115-124.
30. , et al. “Lysosomal dysfunction in Down syndrome and Alzheimer mouse models is caused by v- ATPase inhibition by Tyr682-phosphorylated APP βCTF”. Science Advances 9 (2023): eadg1925.
31. Dangjoon Im and Tae Su Choi. “Distinctive contribution of two additional residues in protein aggregation of Aβ42 and Aβ40 isoforms”. BMB Report 57 (2024): 263-272.
32. Lu Yifei., et al. “Changes in AD Blood Biomarkers and associations with Incident All-cause Dementia”. JAMA (2024).
33. Janelidze Shorena., et al. “Head-to-Head Comparison of 8 Plasma Amyloid-β42/40 Assays in Alzheimer Disease”. JAMA Neurology 78 (2021): 1375-1382.
34. Xia Zengjie., et al. “Co-aggregation with Apolipoprotein E modulates the function of Amyloid-β in AD's disease”. Nature Communication 15 (2024): 4695.
35. Naguib Sarah., et al. “The R136S mutation in the APOE3 gene confers resilience against tau pathology via inhibition of the cGAS-STING-IFN pathway”. Immunity (2025).
36. Nelson Maxine R., et al. “The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegeneration and neuroinflammation”. Nature Neuroscience 26 (2023): 2104-2121.
37. Thijssen Elisabeth H., et al. “Association of Plasma P-tau217 and P-tau181 with clinical phenotype, neuropathology and image markers in Alzheimer’s disease and frontotemporal lobar degeneration: a retrospective”. Lancet Neurology9 (2021): 739-752.
38. Ashton Nicholas J., et al. “Diagnostic Accuracy of a Plasma Phosphorylated Tau217 Immunoassay for Alzheimer Disease Pathology”. NEJM 3 (2024): 255-253.
39. Leuzy Antoine., et al. “Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease”. Alzheimer 's Dementia 21 (2025): e14528.
40. Ashton Nicholas J., et al. “The Alzheimer’s Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau Round Robin study”. Alzheimer's Dementia 21 (2025): e14508.
41. Anthony J Hannan. “Tandem repeats mediating genetic plasticity in health and disease”. Nature Reviews Genetics 19 (2018): 286-298.

Citation

Citation: Rama Shankar Singh. “QED (Quadruplet Expanded DNA) Eukaryote Genetic Code Developmental Journey and Incurable Diseases”.Acta Scientific Medical Sciences 9.9 (2025): 03-15.

Copyright

Copyright: © 2025 Rama Shankar Singh. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.